BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...become more active in the biotech space,” Credit Suisse’s...
BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...conjugates targeting ROR2 and AXL in Phase II testing for solid tumors. J.P. Morgan, Jefferies and Credit Suisse...
BioCentury | Dec 8, 2020
Deals

Dec. 7 Quick Takes: Sino pays $515M for Sinovac stake; plus BioCryst, Roivant, AbCellera, Syros, YZY, Maze

...Canadian biotech would raise $356.5 million at a postmoney valuation of $4.1 billion. Underwriters are Credit Suisse...
BioCentury | Oct 2, 2020
Finance

Sophia aims to parlay expertise of new backers aMoon, Hitachi to grow biopharma business

...sector.Also investing in the series F were Credit Suisse...
BioCentury | Aug 15, 2020
Finance

Big post-IPO gain for CureVac could presage volatile aftermarket

...of the IPO underwriters’ overallotment option would reduce those stakes a bit more.BofA Securities, Jefferies, Credit Suisse...
BioCentury | Jul 13, 2020
Finance

BeiGene’s billions to support new launches, deep pipeline

...announced Sunday. BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) did not use underwriters or placement agents; it said Credit Suisse...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...raised $277.6 million and valued Forma at $778 million. Underwriters are Jefferies, SVB Leerink and Credit Suisse...
...oncology company sold 16 million shares at $16, well above its upsized range of $11.50-$13.50. Credit Suisse...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...has 10.6%, while Eli Lilly and Co. (NYSE:LLY) has 10.4%. Underwriters are Cowen, SVB Leerink, Credit Suisse...
BioCentury | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

...$250 million. Mirati’s lead program targets K-Ras (KRAS). Underwriters are Goldman Sachs, SVB Leerink, Cowen, Credit Suisse...
BioCentury | Dec 12, 2019
Financial News

Momenta, Forty Seven, Assembly push 2019 follow-on tally to $21.5B

...sold 4.9 million shares at $35 a share in a follow-on underwritten by Morgan Stanley, Credit Suisse...
Items per page:
1 - 10 of 968
BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...become more active in the biotech space,” Credit Suisse’s...
BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...conjugates targeting ROR2 and AXL in Phase II testing for solid tumors. J.P. Morgan, Jefferies and Credit Suisse...
BioCentury | Dec 8, 2020
Deals

Dec. 7 Quick Takes: Sino pays $515M for Sinovac stake; plus BioCryst, Roivant, AbCellera, Syros, YZY, Maze

...Canadian biotech would raise $356.5 million at a postmoney valuation of $4.1 billion. Underwriters are Credit Suisse...
BioCentury | Oct 2, 2020
Finance

Sophia aims to parlay expertise of new backers aMoon, Hitachi to grow biopharma business

...sector.Also investing in the series F were Credit Suisse...
BioCentury | Aug 15, 2020
Finance

Big post-IPO gain for CureVac could presage volatile aftermarket

...of the IPO underwriters’ overallotment option would reduce those stakes a bit more.BofA Securities, Jefferies, Credit Suisse...
BioCentury | Jul 13, 2020
Finance

BeiGene’s billions to support new launches, deep pipeline

...announced Sunday. BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) did not use underwriters or placement agents; it said Credit Suisse...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...raised $277.6 million and valued Forma at $778 million. Underwriters are Jefferies, SVB Leerink and Credit Suisse...
...oncology company sold 16 million shares at $16, well above its upsized range of $11.50-$13.50. Credit Suisse...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...has 10.6%, while Eli Lilly and Co. (NYSE:LLY) has 10.4%. Underwriters are Cowen, SVB Leerink, Credit Suisse...
BioCentury | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

...$250 million. Mirati’s lead program targets K-Ras (KRAS). Underwriters are Goldman Sachs, SVB Leerink, Cowen, Credit Suisse...
BioCentury | Dec 12, 2019
Financial News

Momenta, Forty Seven, Assembly push 2019 follow-on tally to $21.5B

...sold 4.9 million shares at $35 a share in a follow-on underwritten by Morgan Stanley, Credit Suisse...
Items per page:
1 - 10 of 968